Parallel chimeric antigen receptors (PCARS) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof
Patent Information
- Application Number
- HK62026127170
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-14
- Filing Date
- 2026-08-06
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST 
Figure 00000000_0001_ABST 
Figure 00000000_0003_ABST 
Figure 00000000_0009_ABST 
Figure 00000000_0008_ABST 
Figure 00000000_0002_ABST 
Figure 00000000_0007_ABST 
Figure 00000000_0004_ABST 
Figure 00000000_0005_ABST 
Figure 00000000_0006_ABST
Abstract
Description
V O 2 0 2 4 / 2 0 9 0 8 4 A 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number WO 2024 / 209084 A1 10 October 2024 (10.10.2024) WIPO PCT (51) International Patent Classification: A61K 39 / 00 (2006.01) C12N 5 / 0783 (2010.01) (21) International Application Number: Cambourne, Cambridge CB23 6HJ (GB). GLOVER, Maya; Leucid Bio Ltd, 30 Broad Street, Great Cambourne, Cambridge CB23 6HJ (GB). MAHER, John; Kings Col- lege London, Strand, London WC2R 2LS (GB). PCT / EP2024 / 059381 (22) International Filing Date: 05 April 2024 (05.04.2024) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2305067.7 2403716.0 05 April 2023 (05.04.2023) GB 14 March 2024 (14.03.2024) GB (71) Applicants: KINGS COLLEGE LONDON [GB / GB]; Strand, London WC2R 2LS (GB). LEUCID BIO LTD [GB / GB]; 30 Broad Street, Great Cambourne, Cambridge CB23 6HJ (GB). (72) Inventors: DUNBAR, Phoebe; Leucid Bio Ltd, 30 Broad Street, Great Cambourne, Cambridge CB23 6HJ (GB). DAVIES, Marc; Leucid Bio Ltd, 30 Broad Street, Great (74) Agent: CHAPMAN, Lee et al.; Greaves Brewster LLP. Copa House, Station Road, Cheddar Somerset BS27 3АH (GB). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP. KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU. MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT. OA, RO. RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV. SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS. ZA, ZM, ZW. (81) (54) Title: PARALLEL CHIMERIC ANTIGEN RECEPTORS (PCARS) AND ADAPTOR CHIMERIC ANTIGEN RECEPTORS COMPRISING ALTERNATIVE SIGNALLING DOMAINS AND METHODS OF USE THEREOF FIG. 1A KEY: TBB / H H2 TBB / H 1XX H2 1XX HMFG2 OT1E CD28 DAP12 41BB FCeR1g CD3z CDва CD3z-1xx FIG. 1B TBB / H-1 TBB / H-14З TBB / H-1A6 TBB / H-1A9 TBB / H-109 YRS αρ FIG. 1C FcER1g DAP12 43aa 46aa 49aa A YRS 49aa (57) Abstract: Provided herein are second generation chimeric antigen receptors (CARs), parallel CARS (PCARs), and adaptor CARs comprising an intracellular signalling domain modified for optimal signalling. Also provided herein are compositions and methods for improving anti-tumour efficacy and restimulation capacity of CAR T-cells, pCAR T-cells, and adaptor CAR T-cells. [Continued on next page] WO 2024 / 209084 A1 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT. LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: - with international search report (Art. 21(3)) - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) - with sequence listing part of description (Rule 5.2(a)) - in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPЕ WO 2024 / 209084 PCT / EP2024 / 059381 PARALLEL CHIMERIC ANTIGEN RECEPTORS (pCARs) AND ADAPTOR CHIMERIC ANTIGEN RECEPTORS COMPRISING ALTERNATIVE SIGNALLING DOMAINS AND METHODS OF USE THEREOF 1. SEQUENCE LISTING
[0001] The instant application contains a Sequence Listing which has been submitted electronically and is hereby incorporated by reference in its entirety. Said XML copy, created on 4 April 2024, is named P4861PC00 Sequence Listing, and is 115,824 bytes in size. 2. BACKGROUND
[0002] Chimeric antigen receptors (CARs), which are at times referred to as artificial T cell receptors, chimeric T cell receptors (cTCR), or chimeric immunoreceptors, are engineered receptors now well known in the art. They are used primarily to transform immune effector cells, in particular T cells, to provide those cells with a desired engineered specificity. Adoptive cell therapies using CAR-T cells are particularly under investigation in the field of cancer therapy. In these therapies, T cells are removed from a patient and modified so that they express CARs specific to the antigens found in a particular form of cancer. The CAR-T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient.
[0003] First generation CARs provide a TCR-like signal, most commonly using a CD3 zeta (CD3) intracellular signalling domain, and thereby elicit tumouricidal functions. However, the engagement of CD3-chain fusion receptors may not suffice to elicit substantial IL-2 secretion and / or T cell proliferation in the absence of a concomitant co- stimulatory signal. In physiological T cell responses, optimal lymphocyte activation requires the engagement of one or more co-stimulatory receptors such as CD28 or 4-1BB.
[0004] Second generation CARs have been constructed to transduce a functional antigen-dependent co-stimulatory signal in human primary T cells in addition to antigen- dependent TCR-like signal, permitting T cell proliferation in addition to tumouricidal activity. Second generation CARs most commonly provide co-stimulation using co- stimulatory domains (synonymously, co-stimulatory signalling regions) derived from CD28 or 4-1BB. The combined delivery of co-stimulation plus a CD3 signal renders second-generation CARs clearly superior in terms of function as compared to their first WO 2024 / 209084 PCT / EP2024 / 059381 generation counterparts (CD3 signal alone). An example of a second generation CAR is found in US Patent No 7,446,190, incorporated herein by reference.
[0005] More recently, so-called third generation CARs have been prepared. These combine multiple co-stimulatory domains (synonymously, co-stimulatory signalling regions) with a TCR-like signalling domain in cis, such as CD28+4-1BB+ CD3 or CD28+OX40+CD3 to further augment potency. In the third generation CARs, the co- stimulatory domains are aligned in series in the CAR endodomain and are generally placed upstream of CD3C or its equivalent.
[0006] In general, however, the results achieved with these third generation CARS have been disappointing, showing only a marginal improvement over second generation configurations, with some third generation CARs being inferior to second generation configurations.
[0007] We have recently described a new format in which immuno-responsive cells such as T cells are engineered to express two constructs in parallel, a 2nd generation CAR and a chimeric co-stimulatory receptor (CCR). The 2nd generation CAR comprises, from C-terminus to N-terminus (from intracellular to extracellular), the following domains: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a first binding element that specifically interacts with a first epitope on a first target antigen. The CCR comprises, from C-terminus to N-terminus (from intracellular to extracellular), (a) a co-stimulatory signalling region which is different from the cо- stimulatory signalling region of the CAR; (b) a transmembrane domain; and (c) a second binding element that specifically interacts with an epitope on a target antigen. The CAR and CCR may recognize an identical epitope, different epitopes on the same antigen, or epitopes found on two distinct antigens. Unlike the CAR, the CCR lacks a TCR-like signalling region such as CD3C. These parallel CAR (pCAR)-engineered T cells demonstrate superior activity and resistance to exhaustion as compared to first generation CAR-T cells, second generation CAR-T cells, and third generation CAR-T cells. See US pre-grant publication 2019 / 0002521 and PCT publications WO 2020 / 183158 and WO 2021 / 0383036, each of which is incorporated herein by reference in its entirety.
[0008] These properties of pCAR-T cells make them attractive candidates for treatment of refractory malignancies, where first, second, and third generation CAR-T cells show limited efficacy in part due to T cell exhaustion. However, there is need for further development of this technology to improve its therapeutic efficacy. 2 WO 2024 / 209084 PCT / EP2024 / 059381 3. SUMMARY
[0009] In one aspect, described herein is a parallel chimeric antigen receptor (pCAR) comprising: (1) a second-generation chimeric antigen receptor (second-generation CAR) comprising: a) an intracellular signalling domain comprising a modified CD3 polypeptide; b) a co-stimulatory signalling region; c) a transmembrane domain; and d) a first binding element that specifically interacts with a first epitope on a first target antigen, wherein the modified CD3Č polypeptide comprises an unmodified immunoreceptor tyrosine-based activation motif 1 (ITAM1), and one or more mutations in ITAM2 and / or ITAM3; and (2) a chimeric co-stimulatory receptor (CCR) comprising at least one CCR polypeptide comprising: e) a co-stimulatory signalling region which is different from that of (b); f) a transmembrane domain; and g) a second binding element that specifically interacts with a second epitope on a second target antigen. The disclosure also provides: - one or more polynucleotide constructs encoding the pCAR of the invention, - one or more expression vectors comprising the one or more polynucleotide constructs of the invention, - an immunoresponsive cell comprising the pCAR of the invention, the one or more polynucleotide constructs of the invention, or the one or more expression vectors of the invention, - a pharmaceutical composition comprising the one or more polynucleotide constructs of the invention, the one or more expression vectors of the invention, or a population of immunoresponsive cells of the invention and an excipient, - the pCAR of the invention, the one or more polynucleotide constructs of the invention, the one or more expression vectors of the invention, the immunoresponsive cell of the invention, or the pharmaceutical composition of the invention for use in therapy, and 3 摘要 本文提供了第二代嵌合抗原受体(CAR)、平行 CAR(pCAR)和衔接子 CAR,其包含 经修饰以获得最佳信号传导的细胞内信号结构域。本文还提供了用于改善 CAR T 细胞、 pCAR T 细胞和衔接子 CAR T 细胞的抗肿瘤效力和再刺激能力的组合物和方法。
Claims
WHAT IS CLAIMED IS:
1. A parallel chimeric antigen receptor (pCAR) comprising: (1) a second-generation chimeric antigen receptor (second-generation CAR) comprising: a) an intracellular signalling domain comprising a modified CD3 ^ polypeptide; b) a co-stimulatory signalling region; c) a transmembrane domain; and d) a first binding element that specifically interacts with a first epitope on a first target antigen, wherein the modified CD3 ^ polypeptide comprises an unmodified immunoreceptor tyrosine- based activation motif 1 (ITAM1), and one or more mutations in ITAM2 and / or ITAM3; and (2) a chimeric co-stimulatory receptor (CCR) comprising at least one CCR polypeptide comprising: e) a co-stimulatory signalling region which is different from that of (b); f) a transmembrane domain; and g) a second binding element that specifically interacts with a second epitope on a second target antigen.
2. The pCAR of claim 1, wherein the modified CD3 ^ polypeptide comprises mutations in both ITAM2 and ITAM3.
3. The pCAR of claim 2, wherein the ITAM2 and the ITAM3 in the modified CD3 ^ are non-functional.
4. The pCAR of any one of claims 1-3, wherein (i) each of the ITAM2 and the ITAM3 comprises at least one Tyr to Phe mutation or two Tyr to Phe mutations or (ii) the modified CD3 ^ polypeptide comprises deletion of ITAM2 or a portion thereof and deletion of ITAM3 or a portion thereof.
5. The pCAR of claim 4, wherein the modified CD3 ^ polypeptide further comprises deletion of one or more amino acid residues on the N-terminal side of the ITAM1.
6. The pCAR of any one of the preceding claims, wherein the modified CD3 ^ polypeptide comprises a sequence selected from SEQ ID NOs: 48-53.
7. The pCAR of any one of the preceding claims, wherein the first target antigen is selected from an NKG2D ligand (e.g., MICA, MICB, ULBP1-ULBP6), MUC1, αvβ6 integrin, ErbB, HER2, B7-H3, Claudin 18.2, Claudin 18.6, Glypican 3, ALK, CD70, and prostate-specific membrane antigen (PSMA).
8. The pCAR of any one of the preceding claims, wherein the first binding element comprises the CDRs of the HMFG2 antibody, the VHand VLdomains of HMFG2 antibody or HMFG2 single-chain variable fragment (scFv).
9. The pCAR of any one of the preceding claims, wherein the second-generation CAR has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
59.
10. The pCAR of any one of the preceding claims, wherein the co-stimulatory signalling region is selected from (i) co-stimulatory signalling regions of members of the B7 / CD28 family, the ILT / CD85 family, the tumour necrosis factor (TNF) superfamily, the SLAM family, and the TIM family, (ii) a CD28 co-stimulatory domain, a 4-1BB co-stimulatory domain, an OX40 co-stimulatory domain, and an ICOS co-stimulatory domain, or (iii) a co- stimulatory molecule selected from CD7, CD96, CD160, CD200, CD300a, CRTAM, DAP10, DAP12, Dectin-1, DPPIV, EphB6, LAG-3, TSLP R, or a variant thereof .
11. The pCAR of claim 10, wherein the CD28 co-stimulatory domain comprises a mutation in the YRS motif.
12. The pCAR of any one of the preceding claims, wherein the co-stimulatory signalling region of (e) is a 4-1BB co-stimulatory domain.
13. The pCAR of any one of the preceding claims, wherein the transmembrane domain is selected from the transmembrane domains of CD8α, CD28, CD4, CD3 ^, FcεR1γ.
14. The pCAR of any one of the preceding claims, wherein the transmembrane domain of (c) is a CD28 transmembrane domain and / or the transmembrane domain of (f) is a CD8α transmembrane domain.
15. The pCAR of any one of the preceding claims, wherein the second target antigen is selected from an NKG2D ligand (e.g., MICA, MICB, ULBP1-ULBP6), MUC1, αvβ6 integrin, ErbB, HER2, B7-H3, GD2, Claudin 18.2, Claudin 18.6, Glypican 3, ALK, CD47, CD70, prostate-specific membrane antigen (PSMA), a PD-1 ligand (e.g., PD-L1), NKp44 ligands (e.g., NKp44L (MLL5), PCNA, viral haemagglutinins, nidogen-1, galectin-3, other proteoglycans) and NKp30 ligands (e.g., BAG6, B7-H6).
16. The pCAR of any one of the preceding claims, wherein the second binding element specifically interacts with an ErbB antigen, an NKG2D ligand, a PD-1 ligand, an NKp44 ligand, or an NKp30 ligand.
17. The pCAR of any one of the preceding claims, wherein the second binding element is any one of a T1E peptide, an NKG2D polypeptide, a PD-1 polypeptide, an NKp44 polypeptide, an NKp30 polypeptide, or a fragment, portion, or variant thereof.
18. The pCAR of any one of the preceding claims, wherein the CCR of (2) comprises two or more CCR polypeptides.
19. The pCAR of any one of the preceding claims, wherein the CCR of (2) comprises three CCR polypeptides.
20. The pCAR of claim 18, wherein the CCR comprises two CCR polypeptides that dimerize following interaction of the second binding element with the second target antigen.
21. The pCAR of claim 19, wherein the three CCR polypeptides trimerize following interaction of the second binding element with the second target antigen.
22. The pCAR of any one of the preceding claims, wherein the second-generation CAR has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 59 and the CCR has at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NO: 24, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, and SEQ ID NO:
83.
23. One or more polynucleotide constructs encoding the pCAR of any one of the preceding claims.
24. One or more expression vectors comprising the one or more polynucleotide constructs of claim 23.
25. An immunoresponsive cell comprising the pCAR of any one of claims 1-22, the one or more polynucleotide constructs of claim 23, or the one or more expression vectors of claim 24.
26. The immunoresponsive cell of claim 25, wherein the immunoresponsive cell is an αβ T cell, γδ T cell, or a Natural Killer (NK) cell.
27. A pharmaceutical composition comprising the one or more polynucleotide constructs of claim 23, the one or more expression vectors of claim 24, or a population of immunoresponsive cells of claim 25 or claim 26 and an excipient.
28. The pCAR of any one of claims 1-22, the one or more polynucleotide constructs of claim 23, the one or more expression vectors of claim 24, the immunoresponsive cell of claim 25 or 26, or the pharmaceutical composition of claim 27 for use in therapy.
29. The pCAR of any one of claims 1-22, the one or more polynucleotide constructs of claim 23, the one or more expression vectors of claim 24, the immunoresponsive cell of claim 25 or 26, or the pharmaceutical composition of claim 27 for use in the treatment of cancer.
30. A fusion polypeptide comprising (i) a DNAX-activating protein 10 (Dap10) polypeptide, or a functional variant thereof and (ii) a modified CD3 ^ polypeptide that comprises an unmodified immunoreceptor tyrosine-based activation motif 1 (ITAM1), and one or more mutations in ITAM2 and / or ITAM3.
31. The fusion polypeptide of claim 30, wherein the Dap10 polypeptide has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
47.
32. The fusion polypeptide of claim 30 or claim 31, wherein the modified CD3 ^ polypeptide comprises mutations in both ITAM2 and ITAM3.
33. The fusion polypeptide of any one of claims 30-32, wherein the ITAM2 and the ITAM3 in the modified CD3 ^ are non-functional.
34. The fusion polypeptide of any one of claims 30-33, wherein (i) each of the ITAM2 and the ITAM 3 comprises at least one Tyr to Phe mutation or two Tyr to Phe mutations or (ii) the modified CD3 ^ polypeptide comprises deletion of ITAM2 or a portion thereof and deletion of ITAM3 or a portion thereof.
35. The fusion polypeptide of any one of claims 30-34, wherein the modified CD3 ^ polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4
